| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10220393 | European Journal of Surgical Oncology (EJSO) | 2018 | 25 Pages |
Abstract
Whereas neoadjuvant FOLFIRINOX rarely achieves resectability in patients with LAPC (10%), most BRPC undergo resection (87%). Neoadjuvant FOLFIRINOX leads to complete pathological response in 13% of cases, tumor downstaging, and a trend towards improved survival compared with patients undergoing up-front surgery.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Alex Barenboim, Guy Lahat, Ravit Geva, Ido Nachmany, Richard Nakache, Yaacov Goykhman, Eli Brazowski, Galia Rosen, Ofer Isakov, Ido Wolf, Joseph M. Klausner, Nir Lubezky,